MADRID, 22 Mar. (EUROPA PRESS) -
Atrys Health registered net losses of 23.5 million euros in 2022, a figure very similar to that of 2021, when it obtained a negative net result of 23.2 million euros, as the company notified the National Market Commission on Wednesday. of Securities (CNMV).
The company dedicated to the provision of medical services has attributed the losses in the year 2022 to the expenses associated with its "strong" inorganic growth, the amortizations of the acquisitions carried out and the optimization of the group structure carried out in 2022. "Without these effects, the net result would have been positive," the company highlighted.
However, in its first year as a member of the Continuous Market of the Spanish Stock Market, Atrys Health increased its turnover by 54.5% compared to the previous year, reaching 186.9 million euros.
For its part, the adjusted gross operating result (Ebitda) grew to 41.3 million euros, representing an increase of 60.5% compared to the 25.7 million of the previous year.
Atrys Health's gross margin in 2022 stood at 149.7 million euros, 52.6% more than in 2021, while at a pro forma level it reached 158.8 million euros.
For its part, investment in capital increased to 14 million euros in 2022, 63.4% more.
In 2022, Atrys boosted its inorganic growth with the acquisition of five companies -SIMM, Bienzobas, ChileRad, Chaxa and Initia-, increased its capital by 83 million euros and partially divested its compliance subsidiary Conversia.
Looking ahead to the 2023 financial year, Atrys has assured that it will focus on consolidating the different lines of business and "on continuing to innovate technologically to offer the most advanced diagnoses and treatments."
Thus, the company has set itself the objective of double-digit growth, specifically between 10% and 13%, both in turnover and adjusted Ebitda.
The executive president of Atrys, Santiago de Torres, has highlighted that the company in 2023 will focus on strengthening the different business areas, "always with an eye on continuing to offer patients the best care service and on creating shareholder value."
